Justin Musinsky

List of Publications by Year
in descending order

186	19,423	15495 65	13365 130
papers	citations	h-index	g-index

194	194	194	23638
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	3.0	19
2	Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes. JCO Oncology Practice, 2022, 18, 201-209.	1.4	34
3	Factors Influencing Patient Preferences for Telehealth Cancer Genetic Counseling During the COVID-19 Pandemic. JCO Oncology Practice, 2022, 18, e462-e471.	1.4	8
4	Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 362-371.	1.1	7
5	Inherited TP53 Variants and Risk of Prostate Cancer. European Urology, 2022, 81, 243-250.	0.9	40
6	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
7	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	2.2	15
8	Early age of onset and broad cancer spectrum persist in MSH6- and PMS2-associated Lynch syndrome. Genetics in Medicine, 2022, 24, 1187-1195.	1.1	7
9	Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1450-1459.	1.1	10
10	SNPs at SMG7 associated with time from biochemical recurrence to prostate cancer death. Cancer Epidemiology Biomarkers and Prevention, 2022, , .	1.1	1
11	Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Nonâ€“Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2022, 28, 4267-4277.	3.2	4
12	Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology, 2021, 160, 1164-1178.e6.	0.6	36
13	Characterization and Clinical Outcomes of DNA Mismatch Repairâ€“deficient Small Bowel Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1429-1437.	3.2	23
14	Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. Clinical Cancer Research, 2021, 27, 1997-2010.	3.2	15
15	Genetically predicted circulating concentrations of micronutrients and risk of colorectal cancer among individuals of European descent: a Mendelian randomization study. American Journal of Clinical Nutrition, 2021, 113, 1490-1502.	2.2	27
16	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. , 2021, 5, 200-217.		0
17	Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut, 2021, 70, 1325-1334.	6.1	44
18	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nature Cancer, 2021, 2, 357-365.	5.7	74

#	Article	IF	Citations
19	Prevalence and Characterization of Biallelic and Monoallelic NTHL1 and MSH3 Variant Carriers From a Pan-Cancer Patient Population. JCO Precision Oncology, 2021, 5, 455-465.	1.5	10
20	Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. Human Molecular Genetics, 2021, 30, 1142-1153.	1.4	2
21	Response to Li and Hopper. American Journal of Human Genetics, 2021, 108, 527-529.	2.6	5
22	Circulating Levels of Testosterone, Sex Hormone Binding Globulin and Colorectal Cancer Risk: Observational and Mendelian Randomization Analyses. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1336-1348.	1.1	15
23	Novel ultra-rare exonic variants identified in a founder population implicate cadherins in schizophrenia. Neuron, 2021, 109, 1465-1478.e4.	3.8	21
24	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	1.1	16
25	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. JAMA Network Open, 2021, 4, e2114753.	2.8	15
26	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	2.6	6
27	Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. Journal of the National Cancer Institute, 2021, , .	3.0	6
28	Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. Genetics in Medicine, 2021, 23, 2105-2113.	1.1	29
29	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. Journal of the National Cancer Institute, 2021, 113, 1683-1692.	3.0	66
30	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. Journal of Clinical Oncology, 2021, 39, 2698-2709.	0.8	83
31	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	2.9	9
32	Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. Npj Breast Cancer, 2021, 7, 135.	2.3	9
33	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. European Urology Oncology, 2021, 4, 993-1000.	2.6	16
34	Clonal hematopoiesis is associated with risk of severe Covid-19. Nature Communications, 2021, 12, 5975.	5.8	81
35	Facilitated cascade testing (FaCT): a randomized controlled trial. International Journal of Gynecological Cancer, 2021, 31, 779-783.	1.2	6
36	Fumarate hydrataseFHc.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma. Human Mutation, 2020, 41, 103-109.	1.1	25

#	Article	IF	Citations
37	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
38	Cumulative Burden of Colorectal Cancerâ€“Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. Gastroenterology, 2020, 158, 1274-1286.e12.	0.6	110
39	Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses. Gastroenterology, 2020, 158, 1300-1312.e20.	0.6	90
40	Identification of Novel Loci and New Risk Variant in Known Loci for Colorectal Cancer Risk in East Asians. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 477-486.	1.1	25
41	Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	0.8	270
42	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	1.1	82
43	A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. Cancer Research, 2020, 80, 3732-3744.	0.4	32
44	Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk. American Journal of Human Genetics, 2020, 107, 432-444.	2.6	124
45	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	9.4	367
46	Circulating bilirubin levels and risk of colorectal cancer: serological and Mendelian randomization analyses. BMC Medicine, 2020, 18, 229.	2.3	28
47	Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk. Journal of Thoracic Oncology, 2020, 15, 1871-1879.	0.5	24
48	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. JCO Precision Oncology, 2020, 4, 916-925.	1.5	9
49	Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. BMC Medicine, 2020, 18, 396.	2.3	76
50	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	9.4	265
51	Protein-altering germline mutations implicate novel genes related to lung cancer development. Nature Communications, 2020, 11, 2220.	5.8	31
52	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	1.6	2
53	Mendelian Randomization of Circulating Polyunsaturated Fatty Acids and Colorectal Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 860-870.	1.1	26
54	Illustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel <i>BRCA1/2</i> Genetic Risk Modifier Test. Public Health Genomics, 2020, 23, 6-19.	0.6	7

#	Article	IF	Citations
55	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	3.4	48
56	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	0.6	32
57	Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening. Journal of Clinical Oncology, 2020, 38, 1398-1408.	0.8	60
58	Characterization of a germline splice site variant MLH1 c.678-3T>A in a Lynch syndrome family. Familial Cancer, 2020, 19, 315-322.	0.9	1
59	11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood. Cancer, 2020, 126, 3114-3121.	2.0	23
60	Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. Nature Communications, 2020, 11, 597.	5.8	193
61	Uptake of oophorectomy in women with findings on multigene panel testing: Results from the Prospective Registry of Multiplex Testing (PROMPT).. Journal of Clinical Oncology, 2020, 38, 1508-1508.	0.8	10
62	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 380-391.	2.3	314
63	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. Journal of the National Cancer Institute, 2019, 111, 146-157.	3.0	129
64	Genetic overlap between autoimmune diseases and nonâ€Hodgkin lymphoma subtypes. Genetic Epidemiology, 2019, 43, 844-863.	0.6	28
65	Tumour lineage shapes BRCA-mediated phenotypes. Nature, 2019, 571, 576-579.	13.7	295
66	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	1.6	5
67	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
68	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	2.9	19
69	BRCA1andBRCA2pathogenic sequence variants in women of African origin or ancestry. Human Mutation, 2019, 40, 1781-1796.	1.1	26
70	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	5.8	90
71	CHEK2 Alleles Predispose to Renal Cancer in Polandâ€”In Reply. JAMA Oncology, 2019, 5, 576.	3.4	1
72	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of Clinical Oncology, 2019, 37, 286-295.	0.8	397

#	Article	IF	Citations
73	Caseâ€“control analysis identifies shared properties of rare germline variation in cancer predisposing genes. European Journal of Human Genetics, 2019, 27, 824-828.	1.4	4
74	Genetic variant predictors of gene expression provide new insight into risk of colorectal cancer. Human Genetics, 2019, 138, 307-326.	1.8	44
75	Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial. BMJ Open, 2019, 9, e031092.	0.8	10
76	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. JCO Precision Oncology, 2019, 3, 1-15.	1.5	7
77	Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2. Cancer Prevention Research, 2019, 12, 599-608.	0.7	6
78	Germline deletion of ETV6 in familial acute lymphoblastic leukemia. Blood Advances, 2019, 3, 1039-1046.	2.5	21
79	A case for expert curation: an overview of cancer curation in the Clinical Genome Resource (ClinGen). Journal of Physical Education and Sports Management, 2019, 5, a004739.	0.5	14
80	Development of Clinical Domain Working Groups for the Clinical Genome Resource (ClinGen): lessons learned and plans for the future. Genetics in Medicine, 2019, 21, 987-993.	1.1	17
81	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	2.6	711
82	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	3.0	30
83	Discovery of common and rare genetic risk variants for colorectal cancer. Nature Genetics, 2019, 51, 76-87.	9.4	377
84	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. Frontiers in Oncology, 2019, 9, 1539.	1.3	6
85	A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. Genetics in Medicine, 2018, 20, 1324-1327.	1.1	31
86	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
87	High-depth whole genome sequencing of an Ashkenazi Jewish reference panel: enhancing sensitivity, accuracy, and imputation. Human Genetics, 2018, 137, 343-355.	1.8	24
88	BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genetics, 2018, 14, e1007752.	1.5	148
89	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for WaldenstrÃ¶m macroglobulinemia. Nature Communications, 2018, 9, 4182.	5.8	15
90	Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer. British Journal of Cancer, 2018, 118, 1639-1647.	2.9	16

#	Article	IF	Citations
91	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncology, 2018, 4, 1228.	3.4	132
92	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.4	54
93	Germline SDHA mutations in children and adults with cancer. Journal of Physical Education and Sports Management, 2018, 4, a002584.	0.5	33
94	Frequency of actionable cancer predisposing germline mutations in patients with lung cancers.. Journal of Clinical Oncology, 2018, 36, 1504-1504.	0.8	2
95	Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. PLoS Genetics, 2018, 14, e1007111.	1.5	30
96	Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. European Journal of Human Genetics, 2017, 25, 432-438.	1.4	26
97	Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer. Breast Cancer Research and Treatment, 2017, 162, 297-306.	1.1	16
98	Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma. Cancer, 2017, 123, 2452-2458.	2.0	12
99	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature Communications, 2017, 8, 14175.	5.8	75
100	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. Npj Breast Cancer, 2017, 3, 22.	2.3	108
101	Multigene Testing for Hereditary Cancer: When, Why, and How. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 741-743.	2.3	7
102	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
103	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
104	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA - Journal of the American Medical Association, 2017, 318, 825.	3.8	366
105	Integrative clinical genomics of metastatic cancer. Nature, 2017, 548, 297-303.	13.7	685
106	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. Lupus Science and Medicine, 2017, 4, e000187.	1.1	15
107	Germline BRCA2 mutations detected in pediatric sequencing studies impact parentsâ€™ evaluation and care. Journal of Physical Education and Sports Management, 2017, 3, a001925.	0.5	17
108	Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. BMC Medical Genomics, 2017, 10, 33.	0.7	111

#	Article	IF	Citations
109	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
110	Educational and Psychosocial Support Needs in Lynch Syndrome: Implementation and Assessment of an Educational Workshop and Support Group. Journal of Genetic Counseling, 2017, 26, 232-243.	0.9	14
111	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	3.0	242
112	Decision-Making Preferences About Secondary Germline Findings That Arise From Tumor Genomic Profiling Among Patients With Advanced Cancers. JCO Precision Oncology, 2017, 1, 1-13.	1.5	6
113	Interest and Attitudes of Patients With Advanced Cancer With Regard to Secondary Germline Findings From Tumor Genomic Profiling. Journal of Oncology Practice, 2017, 13, e590-e601.	2.5	27
114	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precision Oncology, 2017, 2017, 1-16.	1.5	286
115	Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. Journal of Clinical Oncology, 2017, 35, 1262-1263.	0.8	1
116	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	1.1	10
117	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. JAMA Oncology, 2016, 2, 1434.	3.4	189
118	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine, 2016, 375, 443-453.	13.9	1,205
119	Twentyâ€oneâ€“gene recurrence score assay in <scp>BRCA</scp>â€associated versus sporadic breast cancers: Differences based on germline mutation status. Cancer, 2016, 122, 1178-1184.	2.0	42
120	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	2.2	31
121	Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. American Journal of Human Genetics, 2016, 98, 801-817.	2.6	113
122	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
123	A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. Cancer Discovery, 2016, 6, 1267-1275.	7.7	41
124	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	2.2	42
125	The future of clinical cancer genomics. Seminars in Oncology, 2016, 43, 615-622.	0.8	23
126	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5.8	93

#	Article	IF	Citations
127	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
128	Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family. Breast Cancer Research and Treatment, 2016, 160, 447-456.	1.1	16
129	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nature Communications, 2016, 7, 10933.	5.8	94
130	Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature Reviews Clinical Oncology, 2016, 13, 581-588.	12.5	258
131	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncology, 2016, 2, 104.	3.4	270
132	Genomic Biomarkers for Breast Cancer Risk. Advances in Experimental Medicine and Biology, 2016, 882, 1-32.	0.8	42
133	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
134	Outcome of genetic evaluation of patients with kidney cancer referred for suspected hereditary cancer syndromes. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 238.e1-238.e7.	0.8	20
135	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
136	A Germline Variant on Chromosome 4q31.1 Associates with Susceptibility to Developing Colon Cancer Metastasis. PLoS ONE, 2016, 11, e0146435.	1.1	2
137	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
138	Identification of germline genetic mutations in patients with pancreatic cancer. Cancer, 2015, 121, 4382-4388.	2.0	167
139	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	1.1	34
140	Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia. PLoS Genetics, 2015, 11, e1005262.	1.5	128
141	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. Nature Communications, 2015, 6, 5751.	5.8	58
142	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	3.0	428
143	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607.	1.4	40
144	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221

#	Article	IF	Citations
145	Genitourinary Cancers Other than Prostate Cancer in a BRCA -tested Cohort from a Single Institution. European Urology, 2015, 67, 1196-1197.	0.9	0
146	FANCMc.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Human Molecular Genetics, 2015, 24, 5345-5355.	1.4	91
147	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
148	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	1.1	22
149	Tissue-Specific Enrichment of Lymphoma Risk Loci in Regulatory Elements. PLoS ONE, 2015, 10, e0139360.	1.1	5
150	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	1.5	47
151	Variants at IRX4 as prostate cancer expression quantitative trait loci. European Journal of Human Genetics, 2014, 22, 558-563.	1.4	36
152	A decade of discovery in cancer genomics. Nature Reviews Clinical Oncology, 2014, 11, 632-634.	12.5	17
153	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nature Genetics, 2014, 46, 1233-1238.	9.4	147
154	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. American Journal of Human Genetics, 2014, 95, 462-471.	2.6	96
155	Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins. Nature Communications, 2014, 5, 4835.	5.8	156
156	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 1226-1231.	9.4	270
157	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
158	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	1.5	244
159	Gene Patents and Personalized Cancer Care: Impact of the Myriad Case on Clinical Oncology. Journal of Clinical Oncology, 2013, 31, 2743-2748.	0.8	60
160	Genome-wide association studies of cancer predisposition. , 2013, , 10-20.		1
161	Breast cancer risk prediction using the novel germ-line signatures in epigenome regulatory pathways.. Journal of Clinical Oncology, 2013, 31, 1500-1500.	0.8	0
162	Personalized medicine: new genomics, old lessons. Human Genetics, 2011, 130, 3-14.	1.8	173

#	Article	IF	Citations
163	Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer. Clinical Cancer Research, 2010, 16, 2115-2121.	3.2	263
164	Susceptibility Loci Associated with Prostate Cancer Progression and Mortality. Clinical Cancer Research, 2010, 16, 2819-2832.	3.2	74
165	Ethicolegal Aspects of Cancer Genetics. Cancer Treatment and Research, 2010, 155, 1-14.	0.2	8
166	Genomic Profiles for Disease Risk. JAMA - Journal of the American Medical Association, 2008, 299, 1353.	3.8	100
167	Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study. Journal of Clinical Oncology, 2008, 26, 1331-1337.	0.8	522
168	Ethical and Legal Aspects of Cancer Genetic Testing. Seminars in Oncology, 2007, 34, 435-443.	0.8	28
169	Cancer Genetic Testing and Assisted Reproduction. Journal of Clinical Oncology, 2006, 24, 4775-4782.	0.8	107
170	Preimplantation Genetic Diagnosis for Cancer Syndromes. JAMA - Journal of the American Medical Association, 2006, 296, 2727.	3.8	77
171	The "Duty to Warn" a Patient's Family Members About Hereditary Disease Risks. JAMA - Journal of the American Medical Association, 2004, 292, 1469.	3.8	228
172	Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Medical Genetics, 2003, 4, 1.	2.1	106
173	Shared Genetic Susceptibility to Breast Cancer, Brain Tumors, and Fanconi Anemia. Journal of the National Cancer Institute, 2003, 95, 1548-1551.	3.0	183
174	Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2Mutation. New England Journal of Medicine, 2002, 346, 1609-1615.	13.9	1,363
175	Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers. Clinical Cancer Research, 2002, 8, 3813-9.	3.2	29
176	Involvement ofBCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma. , 1998, 23, 323-327.		47
177	A family with three germline mutations in BRCAl and BRCA2. Clinical Genetics, 1998, 54, 215-218.	1.0	13
178	Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in Bâ€cell nonâ€Hodgkin lymphoma. Genes Chromosomes and Cancer, 1998, 23, 323-327.	1.5	1
179	Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nature Genetics, 1997, 17, 79-83.	9.4	630
180	BRCA1: A new marker in the management of patients with breast cancer?. , 1996, 77, 599-601.		2

#	Article	IF	Citations
181	Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genetics, 1996, 13, 126-128.	9.4	282
182	BCL6 Gene Rearrangement and Other Cytogenetic Abnormalities in Diffuse Large Cell Lymphoma. Leukemia and Lymphoma, 1995, 20, 85-89.	0.6	30
183	Chromosome Analysis in the Management of Patients with Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 1992, 7, 275-282.	0.6	21
184	Clonal cytogenetic abnormalities in Hodgkin's disease. Genes Chromosomes and Cancer, 1991, 3, 294-299.	1.5	36
185	18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance. British Journal of Haematology, 1989, 72, 178-183.	1.2	97
186	Leukemic differentiation of a mediastinal germ cell tumor. Genes Chromosomes and Cancer, 1989, 1, 83-87.	1.5	109